Cargando…

Mendelian randomization of circulating proteome identifies actionable targets in heart failure

BACKGROUND: Heart failure (HF) is a prevalent cause of mortality and morbidity. The molecular drivers of HF are still largely unknown. RESULTS: We aimed to identify circulating proteins causally associated with HF by leveraging genome-wide genetic association data for HF including 47,309 cases and 9...

Descripción completa

Detalles Bibliográficos
Autores principales: Moncla, Louis-Hippolyte Minvielle, Mathieu, Samuel, Sylla, Mame Sokhna, Bossé, Yohan, Thériault, Sébastien, Arsenault, Benoit J., Mathieu, Patrick
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9375407/
https://www.ncbi.nlm.nih.gov/pubmed/35964012
http://dx.doi.org/10.1186/s12864-022-08811-2
_version_ 1784767958176759808
author Moncla, Louis-Hippolyte Minvielle
Mathieu, Samuel
Sylla, Mame Sokhna
Bossé, Yohan
Thériault, Sébastien
Arsenault, Benoit J.
Mathieu, Patrick
author_facet Moncla, Louis-Hippolyte Minvielle
Mathieu, Samuel
Sylla, Mame Sokhna
Bossé, Yohan
Thériault, Sébastien
Arsenault, Benoit J.
Mathieu, Patrick
author_sort Moncla, Louis-Hippolyte Minvielle
collection PubMed
description BACKGROUND: Heart failure (HF) is a prevalent cause of mortality and morbidity. The molecular drivers of HF are still largely unknown. RESULTS: We aimed to identify circulating proteins causally associated with HF by leveraging genome-wide genetic association data for HF including 47,309 cases and 930,014 controls. We performed two-sample Mendelian randomization (MR) with multiple cis instruments as well as network and enrichment analysis using data from blood protein quantitative trait loci (pQTL) (2,965 blood proteins) measured in 3,301 individuals. Nineteen blood proteins were causally associated with HF, were not subject to reverse causality and were enriched in ligand-receptor and glycosylation molecules. Network pathway analysis of the blood proteins showed enrichment in NF-kappa B, TGF beta, lipid in atherosclerosis and fluid shear stress. Cross-phenotype analysis of HF identified genetic overlap with cardiovascular drugs, myocardial infarction, parental longevity and low-density cholesterol. Multi-trait MR identified causal associations between HF-associated blood proteins and cardiovascular outcomes. Multivariable MR showed that association of BAG3, MIF and APOA5 with HF were mediated by the blood pressure and coronary artery disease. According to the directional effect and biological action, 7 blood proteins are targets of existing drugs or are tractable for the development of novel therapeutics. Among the pathways, sialyl Lewis x and the activin type II receptor are potential druggable candidates. CONCLUSIONS: Integrative MR analyses of the blood proteins identified causally-associated proteins with HF and revealed pleiotropy of the blood proteome with cardiovascular risk factors. Some of the proteins or pathway related mechanisms could be targeted as novel treatment approach in HF. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12864-022-08811-2.
format Online
Article
Text
id pubmed-9375407
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-93754072022-08-14 Mendelian randomization of circulating proteome identifies actionable targets in heart failure Moncla, Louis-Hippolyte Minvielle Mathieu, Samuel Sylla, Mame Sokhna Bossé, Yohan Thériault, Sébastien Arsenault, Benoit J. Mathieu, Patrick BMC Genomics Research BACKGROUND: Heart failure (HF) is a prevalent cause of mortality and morbidity. The molecular drivers of HF are still largely unknown. RESULTS: We aimed to identify circulating proteins causally associated with HF by leveraging genome-wide genetic association data for HF including 47,309 cases and 930,014 controls. We performed two-sample Mendelian randomization (MR) with multiple cis instruments as well as network and enrichment analysis using data from blood protein quantitative trait loci (pQTL) (2,965 blood proteins) measured in 3,301 individuals. Nineteen blood proteins were causally associated with HF, were not subject to reverse causality and were enriched in ligand-receptor and glycosylation molecules. Network pathway analysis of the blood proteins showed enrichment in NF-kappa B, TGF beta, lipid in atherosclerosis and fluid shear stress. Cross-phenotype analysis of HF identified genetic overlap with cardiovascular drugs, myocardial infarction, parental longevity and low-density cholesterol. Multi-trait MR identified causal associations between HF-associated blood proteins and cardiovascular outcomes. Multivariable MR showed that association of BAG3, MIF and APOA5 with HF were mediated by the blood pressure and coronary artery disease. According to the directional effect and biological action, 7 blood proteins are targets of existing drugs or are tractable for the development of novel therapeutics. Among the pathways, sialyl Lewis x and the activin type II receptor are potential druggable candidates. CONCLUSIONS: Integrative MR analyses of the blood proteins identified causally-associated proteins with HF and revealed pleiotropy of the blood proteome with cardiovascular risk factors. Some of the proteins or pathway related mechanisms could be targeted as novel treatment approach in HF. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12864-022-08811-2. BioMed Central 2022-08-13 /pmc/articles/PMC9375407/ /pubmed/35964012 http://dx.doi.org/10.1186/s12864-022-08811-2 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Moncla, Louis-Hippolyte Minvielle
Mathieu, Samuel
Sylla, Mame Sokhna
Bossé, Yohan
Thériault, Sébastien
Arsenault, Benoit J.
Mathieu, Patrick
Mendelian randomization of circulating proteome identifies actionable targets in heart failure
title Mendelian randomization of circulating proteome identifies actionable targets in heart failure
title_full Mendelian randomization of circulating proteome identifies actionable targets in heart failure
title_fullStr Mendelian randomization of circulating proteome identifies actionable targets in heart failure
title_full_unstemmed Mendelian randomization of circulating proteome identifies actionable targets in heart failure
title_short Mendelian randomization of circulating proteome identifies actionable targets in heart failure
title_sort mendelian randomization of circulating proteome identifies actionable targets in heart failure
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9375407/
https://www.ncbi.nlm.nih.gov/pubmed/35964012
http://dx.doi.org/10.1186/s12864-022-08811-2
work_keys_str_mv AT monclalouishippolyteminvielle mendelianrandomizationofcirculatingproteomeidentifiesactionabletargetsinheartfailure
AT mathieusamuel mendelianrandomizationofcirculatingproteomeidentifiesactionabletargetsinheartfailure
AT syllamamesokhna mendelianrandomizationofcirculatingproteomeidentifiesactionabletargetsinheartfailure
AT bosseyohan mendelianrandomizationofcirculatingproteomeidentifiesactionabletargetsinheartfailure
AT theriaultsebastien mendelianrandomizationofcirculatingproteomeidentifiesactionabletargetsinheartfailure
AT arsenaultbenoitj mendelianrandomizationofcirculatingproteomeidentifiesactionabletargetsinheartfailure
AT mathieupatrick mendelianrandomizationofcirculatingproteomeidentifiesactionabletargetsinheartfailure